Moreover, it has been proposed that endoxifen reduces ER-α protein levels by targeting it for degradation by the proteasome, while TAM and 4-hydroxytamoxifen stabilize ERα in breast cancer cells [11]. The gene discussed is ESR1; the disease is breast cancer.